Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway

Alina Fomovska, Qingqing Huang, Kamal El Bissati, Ernest J. Mui, William H. Witola, Gang Cheng, Ying Zhou, Caroline Sommerville, Craig W. Roberts, Sam Bettis, Sean T. Prigge, Gustavo A. Afanador, Mark R. Hickman, Patty J. Lee, Susan E. Leed, Jennifer M. Auschwitz, Marco Pieroni, Jozef Stec, Stephen P. Muench, David W. Rice & 2 others Alan P. Kozikowski, Rima McLeod

Research output: Research - peer-reviewArticle

Abstract

Toxoplasma gondii is a protozoan parasite that can damage the human brain and eyes. There are no curative medicines. Herein, we describe our discovery of N-benzoyl-2-hydroxybenzamides as a class of compounds effective in the low nanomolar range against T. gondii in vitro and in vivo. Our lead compound, QQ-437, displays robust activity against the parasite and could be useful as a new scaffold for development of novel and improved inhibitors of T. gondii. Our genome-wide investigations reveal a specific mechanism of resistance to N-benzoyl-2-hydroxybenzamides mediated by adaptin-3β, a large protein from the secretory protein complex. N-Benzoyl-2-hydroxybenzamide-resistant clones have alterations of their secretory pathway, which traffics proteins to micronemes, rhoptries, dense granules, and acidocalcisomes/plant-like vacuole (PLVs). N-Benzoyl-2-hydroxybenzamide treatment also alters micronemes, rhoptries, the contents of dense granules, and, most markedly, acidocalcisomes/PLVs. Furthermore, QQ-437 is active against chloroquine- resistant Plasmodium falciparum. Our studies reveal a novel class of compounds that disrupts a unique secretory pathway of T. gondii, with the potential to be used as scaffolds in the search for improved compounds to treat the devastating diseases caused by apicomplexan parasites.

LanguageEnglish (US)
Pages2666-2682
Number of pages17
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number5
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Secretory Pathway
Toxoplasma
Parasites
2-hydroxybenzamide
Proteins
Vacuoles
Chloroquine
Plasmodium falciparum
Clone Cells
Genome
Brain
Lead
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Fomovska, A., Huang, Q., El Bissati, K., Mui, E. J., Witola, W. H., Cheng, G., ... McLeod, R. (2012). Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrobial Agents and Chemotherapy, 56(5), 2666-2682. DOI: 10.1128/AAC.06450-11

Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. / Fomovska, Alina; Huang, Qingqing; El Bissati, Kamal; Mui, Ernest J.; Witola, William H.; Cheng, Gang; Zhou, Ying; Sommerville, Caroline; Roberts, Craig W.; Bettis, Sam; Prigge, Sean T.; Afanador, Gustavo A.; Hickman, Mark R.; Lee, Patty J.; Leed, Susan E.; Auschwitz, Jennifer M.; Pieroni, Marco; Stec, Jozef; Muench, Stephen P.; Rice, David W.; Kozikowski, Alan P.; McLeod, Rima.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 5, 05.2012, p. 2666-2682.

Research output: Research - peer-reviewArticle

Fomovska, A, Huang, Q, El Bissati, K, Mui, EJ, Witola, WH, Cheng, G, Zhou, Y, Sommerville, C, Roberts, CW, Bettis, S, Prigge, ST, Afanador, GA, Hickman, MR, Lee, PJ, Leed, SE, Auschwitz, JM, Pieroni, M, Stec, J, Muench, SP, Rice, DW, Kozikowski, AP & McLeod, R 2012, 'Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway' Antimicrobial Agents and Chemotherapy, vol 56, no. 5, pp. 2666-2682. DOI: 10.1128/AAC.06450-11
Fomovska A, Huang Q, El Bissati K, Mui EJ, Witola WH, Cheng G et al. Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrobial Agents and Chemotherapy. 2012 May;56(5):2666-2682. Available from, DOI: 10.1128/AAC.06450-11
Fomovska, Alina ; Huang, Qingqing ; El Bissati, Kamal ; Mui, Ernest J. ; Witola, William H. ; Cheng, Gang ; Zhou, Ying ; Sommerville, Caroline ; Roberts, Craig W. ; Bettis, Sam ; Prigge, Sean T. ; Afanador, Gustavo A. ; Hickman, Mark R. ; Lee, Patty J. ; Leed, Susan E. ; Auschwitz, Jennifer M. ; Pieroni, Marco ; Stec, Jozef ; Muench, Stephen P. ; Rice, David W. ; Kozikowski, Alan P. ; McLeod, Rima. / Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 5. pp. 2666-2682
@article{9163db09933a4275acd02d5426e247eb,
title = "Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway",
abstract = "Toxoplasma gondii is a protozoan parasite that can damage the human brain and eyes. There are no curative medicines. Herein, we describe our discovery of N-benzoyl-2-hydroxybenzamides as a class of compounds effective in the low nanomolar range against T. gondii in vitro and in vivo. Our lead compound, QQ-437, displays robust activity against the parasite and could be useful as a new scaffold for development of novel and improved inhibitors of T. gondii. Our genome-wide investigations reveal a specific mechanism of resistance to N-benzoyl-2-hydroxybenzamides mediated by adaptin-3β, a large protein from the secretory protein complex. N-Benzoyl-2-hydroxybenzamide-resistant clones have alterations of their secretory pathway, which traffics proteins to micronemes, rhoptries, dense granules, and acidocalcisomes/plant-like vacuole (PLVs). N-Benzoyl-2-hydroxybenzamide treatment also alters micronemes, rhoptries, the contents of dense granules, and, most markedly, acidocalcisomes/PLVs. Furthermore, QQ-437 is active against chloroquine- resistant Plasmodium falciparum. Our studies reveal a novel class of compounds that disrupts a unique secretory pathway of T. gondii, with the potential to be used as scaffolds in the search for improved compounds to treat the devastating diseases caused by apicomplexan parasites.",
author = "Alina Fomovska and Qingqing Huang and {El Bissati}, Kamal and Mui, {Ernest J.} and Witola, {William H.} and Gang Cheng and Ying Zhou and Caroline Sommerville and Roberts, {Craig W.} and Sam Bettis and Prigge, {Sean T.} and Afanador, {Gustavo A.} and Hickman, {Mark R.} and Lee, {Patty J.} and Leed, {Susan E.} and Auschwitz, {Jennifer M.} and Marco Pieroni and Jozef Stec and Muench, {Stephen P.} and Rice, {David W.} and Kozikowski, {Alan P.} and Rima McLeod",
year = "2012",
month = "5",
doi = "10.1128/AAC.06450-11",
volume = "56",
pages = "2666--2682",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway

AU - Fomovska,Alina

AU - Huang,Qingqing

AU - El Bissati,Kamal

AU - Mui,Ernest J.

AU - Witola,William H.

AU - Cheng,Gang

AU - Zhou,Ying

AU - Sommerville,Caroline

AU - Roberts,Craig W.

AU - Bettis,Sam

AU - Prigge,Sean T.

AU - Afanador,Gustavo A.

AU - Hickman,Mark R.

AU - Lee,Patty J.

AU - Leed,Susan E.

AU - Auschwitz,Jennifer M.

AU - Pieroni,Marco

AU - Stec,Jozef

AU - Muench,Stephen P.

AU - Rice,David W.

AU - Kozikowski,Alan P.

AU - McLeod,Rima

PY - 2012/5

Y1 - 2012/5

N2 - Toxoplasma gondii is a protozoan parasite that can damage the human brain and eyes. There are no curative medicines. Herein, we describe our discovery of N-benzoyl-2-hydroxybenzamides as a class of compounds effective in the low nanomolar range against T. gondii in vitro and in vivo. Our lead compound, QQ-437, displays robust activity against the parasite and could be useful as a new scaffold for development of novel and improved inhibitors of T. gondii. Our genome-wide investigations reveal a specific mechanism of resistance to N-benzoyl-2-hydroxybenzamides mediated by adaptin-3β, a large protein from the secretory protein complex. N-Benzoyl-2-hydroxybenzamide-resistant clones have alterations of their secretory pathway, which traffics proteins to micronemes, rhoptries, dense granules, and acidocalcisomes/plant-like vacuole (PLVs). N-Benzoyl-2-hydroxybenzamide treatment also alters micronemes, rhoptries, the contents of dense granules, and, most markedly, acidocalcisomes/PLVs. Furthermore, QQ-437 is active against chloroquine- resistant Plasmodium falciparum. Our studies reveal a novel class of compounds that disrupts a unique secretory pathway of T. gondii, with the potential to be used as scaffolds in the search for improved compounds to treat the devastating diseases caused by apicomplexan parasites.

AB - Toxoplasma gondii is a protozoan parasite that can damage the human brain and eyes. There are no curative medicines. Herein, we describe our discovery of N-benzoyl-2-hydroxybenzamides as a class of compounds effective in the low nanomolar range against T. gondii in vitro and in vivo. Our lead compound, QQ-437, displays robust activity against the parasite and could be useful as a new scaffold for development of novel and improved inhibitors of T. gondii. Our genome-wide investigations reveal a specific mechanism of resistance to N-benzoyl-2-hydroxybenzamides mediated by adaptin-3β, a large protein from the secretory protein complex. N-Benzoyl-2-hydroxybenzamide-resistant clones have alterations of their secretory pathway, which traffics proteins to micronemes, rhoptries, dense granules, and acidocalcisomes/plant-like vacuole (PLVs). N-Benzoyl-2-hydroxybenzamide treatment also alters micronemes, rhoptries, the contents of dense granules, and, most markedly, acidocalcisomes/PLVs. Furthermore, QQ-437 is active against chloroquine- resistant Plasmodium falciparum. Our studies reveal a novel class of compounds that disrupts a unique secretory pathway of T. gondii, with the potential to be used as scaffolds in the search for improved compounds to treat the devastating diseases caused by apicomplexan parasites.

UR - http://www.scopus.com/inward/record.url?scp=84859805655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859805655&partnerID=8YFLogxK

U2 - 10.1128/AAC.06450-11

DO - 10.1128/AAC.06450-11

M3 - Article

VL - 56

SP - 2666

EP - 2682

JO - Antimicrobial Agents and Chemotherapy

T2 - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -